Marshall Wace
KLRS

Marshall Wace’s Kalaris Therapeutics KLRS Stock Holding History

Marshall Wace’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$392K Sell
67,879
-4,997
-7% -$44.3K ﹤0.01% 2551
2025
Q4 		$615K Buy
72,876
+58,761
+416% +$376K ﹤0.01% 2158
2025
Q3 		$81.6K Hold
14,115
– – ﹤0.01% 2678
2025
Q2 		$37.7K Hold
14,115
– – ﹤0.01% 2615
2025
Q1 		$113K Sell
14,115
-1
-0% -$10 ﹤0.01% 2487
2024
Q4 		$136K Hold
14,116
– – ﹤0.01% 2410
2024
Q3 		$263K Hold
14,116
– – ﹤0.01% 2200
2024
Q2 		$234K Sell
14,116
-1,759
-11% -$31.1K ﹤0.01% 2244
2024
Q1 		$274K Buy
15,875
+1,759
+12% +$28.7K ﹤0.01% 2142
2023
Q4 		$221K Hold
14,116
– – ﹤0.01% 1956
2023
Q3 		$698K Hold
14,116
– – ﹤0.01% 1613
2023
Q2 		$1.1M Hold
14,116
– – ﹤0.01% 1673
2023
Q1 		$1.28M Hold
14,116
– – ﹤0.01% 1696
2022
Q4 		$1.67M Hold
14,116
– – ﹤0.01% 1826
2022
Q3 		$2.56M Hold
14,116
– – 0.01% 1850
2022
Q2 		$1.27M Hold
14,116
– – ﹤0.01% 2300
2022
Q1 		$2.19M Sell
14,116
-131
-0.9% -$26.1K ﹤0.01% 1994
2021
Q4 		$4.24M Buy
+14,247
New +$6.61M 0.01% 1486
2021
Q2 		– Sell
-6,650
Closed -$3.58M – 3184
2021
Q1 		$3.58M Buy
6,650
+6,292
+1,758% +$5.29M 0.02% 1020
2020
Q4 		$316K Sell
358
-694
-66% -$534K ﹤0.01% 1634
2020
Q3 		$666K Buy
+1,052
New +$718K ﹤0.01% 1158

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Marshall Wace's KLRS Position: Q1 2026 in Review

Marshall Wace reduced its Kalaris Therapeutics (KLRS) stake by 6.9% in Q1 2026, selling an estimated $44.3K and leaving 67,879 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #2551.

Marshall Wace first reported a position in KLRS in Q3 2020 and has held it in 21 quarters since. The position peaked at $4.24M in Q4 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Marshall Wace held 67,879 shares of Kalaris Therapeutics worth $392K as of Q1 2026.
  • Marshall Wace sold 4,997 Kalaris Therapeutics shares in Q1 2026, an estimated $44.3K.
  • Kalaris Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2551 holding.
  • Marshall Wace first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Marshall Wace's Kalaris Therapeutics position peaked at $4.24M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.